Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 11:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 1,357 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Resolution Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

Treating Contact Lens Discomfort With Varenicline Solution Nasal Spray 0.03mg

NCT07705893
View directory record Official record
Conditions
Dry Eye
Interventions
Tyrvaya
Drug
Lead sponsor
Ocular Aesthetics, LLC dba Ocular Clinical Trials
Other
Eligibility
18 Years to 99 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 28, 2026, 11:25 AM EDT
Recruiting No phase listed Observational

Characterizing the Microvascular Environment of Bladder Cancer With Super-Resolution Ultrasound Localization Microscopy

NCT06986304
View directory record Official record
Conditions
Bladder Cancer
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 28, 2026, 11:25 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis and Chronic Burkholderia Species Infection

NCT01059565
View directory record Official record
Conditions
Cystic Fibrosis, Burkholderia Infections
Interventions
AZLI, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
34
States / cities
Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2014 · Synced Oct 28, 2026, 11:25 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy of SDP-4 in Subjects With Dry Eye Disease (DED) (SDP-4-CS202)

NCT04535947
View directory record Official record
Conditions
Dry Eye
Interventions
Vehicle, SDP-4 Ophthalmic Solution (1.0%)
Drug
Lead sponsor
Silk Technologies, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Garden Grove, California • Murrieta, California • Newport Beach, California + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Oct 28, 2026, 11:25 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study of MP-376 to Prevent Acute Exacerbations in Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT00739648
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
MP-376, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
40 Years and older
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
39
States / cities
Haleyville, Alabama • Hueytown, Alabama • Mobile, Alabama + 36 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 28, 2026, 11:25 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment Uveitis

NCT01505088
View directory record Official record
Conditions
Anterior Uveitis
Interventions
40 mg/mL Dexamethasone phosphate ophthalmic solution, Prednisolone Acetate (1%) Eyedrops, 100 mM sodium citrate buffer solution, Placebo Eyedrops
Drug
Lead sponsor
Eyegate Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 85 Years
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
39
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2013 · Synced Oct 28, 2026, 11:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Split Dose Golytely With Amitiza Pretreatment Versus Split Dose Golytely Plus Placebo in Outpatient Colonoscopy

NCT00611442
View directory record Official record
Conditions
Bowel Preparation for Colonoscopy
Interventions
lubiprostone, placebo
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2012 · Synced Oct 28, 2026, 11:25 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With Presbyopia

NCT05646719
View directory record Official record
Conditions
Presbyopia
Interventions
Phentolamine Opthalmic Solution 0.75%, Placebo, Low dose pilocarpine, Low dose pilocarpine vehicle
Drug · Other
Lead sponsor
Opus Genetics, Inc
Industry
Eligibility
40 Years to 64 Years
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
26
States / cities
Phoenix, Arizona • Azusa, California • Newport Beach, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 28, 2026, 11:25 AM EDT
Completed Phase 3 Interventional

Assessment of the Safety and Efficacy of BRM421 Ophthalmic Solutions in Dry Eye Subjects.

NCT05695781
View directory record Official record
Conditions
Dry Eye Disease
Interventions
BRM421 Ophthalmic Solution, Vehicle
Drug
Lead sponsor
BRIM Biotechnology Inc.
Industry
Eligibility
18 Years and older
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Warwick, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Oct 28, 2026, 11:25 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Lifitegrast 5% Ophthalmic Solution and Contact Lens Dryness

NCT03686878
View directory record Official record
Conditions
Contact Lens, Contact Lens Discomfort, Contact Lens Dryness
Interventions
Lifitegrast
Drug
Lead sponsor
EV Clinical Trials
Other
Eligibility
21 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2018 · Synced Oct 28, 2026, 11:25 AM EDT
Completed Phase 2 Interventional Results available

A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study

NCT03216902
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
Vehicle of DE-126 Ophthalmic Solution, high dose of DE-126 Ophthalmic Solution, Topical ultra-low dose of DE-126 Ophthalmic Solution, Topical low dose of DE-126 Ophthalmic Solution, Topical medium dose of DE-126 Ophthalmic Solution, Topical high dose of DE-126 Ophthalmic Solution, 0.005% Latanoprost Ophthalmic Solution
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
12
States / cities
Artesia, California • Mission Hills, California • Newport Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2020 · Synced Oct 28, 2026, 11:25 AM EDT
Completed Phase 1 Interventional

Amiloride Solution and Tobramycin Solution for Inhalation for the Eradication of Burkholderia Dolosa in Patients With Cystic Fibrosis

NCT00547053
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Amiloride Solution for Inhalation
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 13, 2011 · Synced Oct 28, 2026, 11:25 AM EDT
Completed Phase 2 Interventional

Evaluating SPRC-AB01 in Post-Surgical Subjects With Chronic Sinusitis

NCT00447837
View directory record Official record
Conditions
Chronic Sinusitis
Interventions
SPRC-AB01
Drug
Lead sponsor
Naryx Pharma
Industry
Eligibility
16 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
43
States / cities
Hoover, Alabama • Jonesboro, Arkansas • Fresno, California + 40 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2008 · Synced Oct 28, 2026, 11:25 AM EDT
Completed Phase 2 Interventional

Inhaled Iloprost in Adults With Abnormal Pulmonary Pressure and Associated With Idiopathic Pulmonary Fibrosis

NCT00109681
View directory record Official record
Conditions
Pulmonary Fibrosis, Pulmonary Hypertension
Interventions
Iloprost Inhalation Solution (Ventavis)
Drug
Lead sponsor
Actelion
Industry
Eligibility
40 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
17
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2010 · Synced Oct 28, 2026, 11:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Open-label, Bioequivalence Study of Certolizumab Pegol 200 mg Solution Injected Either by a Prefilled Syringe (Reference) or by an E-Device (Test) in Healthy Subjects

NCT02806219
View directory record Official record
Conditions
Healthy
Interventions
Prefilled syringe (PFS), e-Device
Device
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 17, 2016 · Synced Oct 28, 2026, 11:25 AM EDT
Completed Phase 2 Interventional

A Clinical Study Evaluating the Safety and Efficacy of SI-614 Ophthalmic Solution in Patients With Dry Eye

NCT01558999
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
High concentration SI-614, Low concentration SI-614, Vehicle
Drug
Lead sponsor
Seikagaku Corporation
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 11, 2023 · Synced Oct 28, 2026, 11:25 AM EDT
Completed Phase 3 Interventional Results available

Tiotropium / Respimat One-Year Study

NCT00168844
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium Inhalation Solution, Placebo
Drug · Other
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
983 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
12
States / cities
Los Angeles, California • Pismo Beach, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 28, 2026, 11:25 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of Prednisolone in a Modified Conjunctival Allergen Challenge Model

NCT01730872
View directory record Official record
Conditions
Chronic Allergic Conjunctivitis
Interventions
Prednisolone Sodium Phosphate Ophthalmic Solution 1%, Tears Naturale II Ophthalmic Solution
Drug
Lead sponsor
ORA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 19, 2019 · Synced Oct 28, 2026, 11:25 AM EDT
Not listed No phase listed Observational

HR-EGG in Medically Refractory Gastroparesis

NCT05789511
View directory record Official record
Conditions
Gastroparesis, Lung Transplant; Complications
Interventions
High Resolution Electrogastography
Device
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Houston, Texas • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 31, 2023 · Synced Oct 28, 2026, 11:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Prospective Cohort Study of Accelerated Resolution Therapy (ART) for Treatment of Military Psychological Trauma

NCT02030522
View directory record Official record
Conditions
Post-traumatic Stress Disorder (PTSD)
Interventions
Accelerated Resolution Therapy (ART)
Behavioral
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
8
States / cities
Clearwater, Florida • Holiday, Florida • Jupiter, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Oct 28, 2026, 11:25 AM EDT
Terminated Not applicable Interventional

Assessment of Heart Failure (HF) At-Home Management Solution ADI Cardio Pulmonary Monitoring System (CPM)

NCT05980585
View directory record Official record
Conditions
Heart Failure
Interventions
CPM Device
Device
Lead sponsor
Analog Device, Inc.
Other
Eligibility
18 Years to 60 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Jacksonville Beach, Florida
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 28, 2026, 11:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Does a Virtual Coach Offer a Better Solution for Weight Reduction in Ventral Hernia Patients With Obesity?

NCT05797974
View directory record Official record
Conditions
Obesity, Ventral Hernia
Interventions
MyChart enabled virtual weight loss coach, Standard preoperative weight loss tools
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 90 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Oct 28, 2026, 11:25 AM EDT
Completed Phase 2 Interventional

The Study Evaluating the Efficacy and Safety of OK-101 in Subjects With Dry Eye Disease

NCT05759208
View directory record Official record
Conditions
Dry Eye Disease
Interventions
OK-101, Placebo
Drug
Lead sponsor
Okyo Pharma Ltd
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
6
States / cities
Newport Beach, California • Colorado Springs, Colorado • Louisville, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2024 · Synced Oct 28, 2026, 11:25 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Experimental Peri-implant Mucositis on Implant Sites That Were Previously Treated With or Without Implantoplasty

NCT06063876
View directory record Official record
Conditions
Peri-implant Mucositis, Peri-Implantitis
Interventions
Induction of experimental peri-implant mucositis, Resolution of experimental peri-implant mucositis
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 28, 2026, 11:25 AM EDT